Equities

Deva Holding AS

DEVA.E:IST

Deva Holding AS

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (TRY)88.60
  • Today's Change-1.10 / -1.23%
  • Shares traded1.04m
  • 1 Year change+86.13%
  • Beta0.9199
Data delayed at least 15 minutes, as of Jun 07 2024 16:09 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Deva Holding AS is a Turkey-based pharmaceutical company that is primarily engaged in the production and marketing of finished pharmaceutical products, pharmaceutical ingredients and veterinary products, as well as animal health products, among others. The Company has four production facilities in Turkey. Its production facilities include the Tokapi, Cerezkoy I, Cerezkoy II and Kartepe production plants. The Company’s product portfolio comprises 73 drugs, which are available on the market in 177 various forms. It offers products, such as Azitro, Alemax, Cefax, Inhibace, Imatis, Hydrea, Kardozin, Kristapen, Magcar, Magnesie Calcinee, Nostil, Oceral, Remidon, Prolixin and Quet, among others. The Company has two subsidiaries, namely Vetaa Veteriner ve Tarim Ilaclari A.S. and Deva Holding NZ Ltd.

  • Revenue in TRY (TTM)11.33bn
  • Net income in TRY3.39bn
  • Incorporated1958
  • Employees2.91k
  • Location
    Deva Holding ASKucukcekmeceISTANBUL 34303TurkeyTUR
  • Phone+90 2 126929292
  • Fax+90 2 126970208
  • Websitehttps://www.deva.com.tr
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Carbios SA837.84k-950.39m14.67bn134.00--1.79--17,512.44-2.03-2.030.001713.920.0001--0.7619179.10-11.20-9.92-12.13-10.77-4,783.33---113,433.30-3,365.229.43-23.970.1517---65.71-53.321.86--141.01--
Nykode Therapeutics ASA338.72m-1.27bn15.08bn176.00--2.97--44.53-1.40-1.400.37225.140.0534--91.80648,333.60-20.015.65-22.976.38-----374.7718.13----0.0313--79.99282.1717.75--187.37--
Idorsia Ltd5.10bn-2.02bn15.18bn938.00------2.98-0.3534-0.35340.7363-4.970.19120.1645113.09150,766.50-7.56-46.72-12.46-53.8493.05---39.51-709.801.00-26.265.82--56.9320.2564.01---8.01--
Medincell SA378.67m-922.36m15.88bn138.00------41.94-1.02-1.020.4086-0.89650.2605--6.8175,853.15-63.46-59.54-115.15-117.3660.4368.38-243.58-451.26---4.291.69--141.788.96-29.04---2.87--
Guerbet SA27.43bn833.16m16.00bn2.92k20.151.215.500.58321.801.8062.1529.970.79970.59835.80269,071.902.261.402.961.8678.0176.022.821.821.215.620.503557.824.30-0.0993158.05-12.615.23-10.07
Pharmanutra SpA3.50bn378.01m16.46bn111.0043.148.2134.494.701.131.1310.435.930.91230.52334.00955,428.609.8518.3913.2024.8095.9296.3610.7917.771.8734.930.332452.5121.1316.51-14.738.4475.7111.20
Gen Ilac ve Saglik Urnlr Snyi ve Tcrt AS10.31bn512.01m18.33bn622.0035.803.2222.221.781.711.7134.3618.981.5911.669.2516,573,770.007.7112.3911.2517.5320.6419.064.856.951.1512.660.2079---23.3847.18-28.97147.97----
Valneva SE5.34bn-851.56m18.52bn684.00--2.8010.373.47-0.1943-0.19431.101.360.27992.345.63223,622.80-4.46-15.39-6.84-25.0632.9535.94-15.95-34.952.22-2.690.528---57.466.3429.21--35.18--
Deva Holding AS11.33bn3.39bn18.56bn2.91k5.481.264.561.6416.9316.9356.6573.920.52721.638.013,896,257.0015.7514.8023.0221.7341.8941.8529.8824.771.07--0.27062.3630.0461.21297.7990.1069.34--
Pharming Group N.V.8.30bn-346.53m19.01bn415.00--2.8767.632.29-0.016-0.0160.36010.28140.59760.56777.21572,833.00-2.505.26-3.616.6388.5789.41-4.189.261.16-7.420.4481--19.309.01-177.14---13.04--
Basilea Pharmaceutica AG Allschwil5.69bn376.92m20.16bn147.0048.43--46.393.550.87650.876513.15-0.83350.79991.065.161,072,340.005.30-1.867.69-2.9983.0083.456.63-2.992.642.021.10--6.683.53-13.96--11.17--
Philogen SpA807.47m-215.08m21.54bn160.00--9.38--26.68-0.1551-0.15510.57472.250.18876.657.95144,562.50-5.03-7.32-5.56-8.3640.0432.04-26.64-58.666.84--0.1414---2.4610.80-14.60--51.78--
Boiron SA17.22bn1.25bn21.56bn2.81k17.061.5511.161.252.062.0628.4122.670.7151.405.26175,533.104.924.596.165.7672.6074.026.886.801.50--0.033853.86-7.67-3.98-19.80-9.01-17.68-1.42
Surgical Science Sweden AB2.58bn637.53m22.37bn265.0035.081.5927.558.674.084.0816.5189.920.17491.686.123,238,531.004.324.494.594.7868.5970.0624.7023.753.53--0.000.0010.0168.1424.47--38.57--
Data as of Jun 07 2024. Currency figures normalised to Deva Holding AS's reporting currency: Turkish Lira TRY

Institutional shareholders

0.26%Per cent of shares held by top holders
HolderShares% Held
Dimensional Fund Advisors LPas of 09 May 2024430.29k0.22%
Dimensional Fund Advisors Ltd.as of 30 Apr 202431.76k0.02%
AK Asset Management ASas of 30 Jun 202215.00k0.01%
Legal & General Investment Management Ltd.as of 30 Apr 202412.25k0.01%
Handelsbanken Fonder ABas of 31 May 20249.86k0.01%
DBX Advisors LLCas of 10 May 20247.28k0.00%
Amundi Asset Management SA (Investment Management)as of 08 May 20243.87k0.00%
DFA Australia Ltd.as of 31 Dec 20231.62k0.00%
Goldman Sachs Asset Management LPas of 10 May 20241.17k0.00%
More ▼
Data from 30 Jun 2022 - 06 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.